Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 708 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced or Metastatic Solid Tumors
Interventions
MDK-703, Checkpoint Inhibitor, Immune
Drug
Lead sponsor
Medikine, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Sarasota, Florida • Huntersville, North Carolina • Austin, Texas + 3 more
Conditions
HIV Infections
Interventions
Thymalfasin, Interleukin-2, Polyethylene Glycolated, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Stanford, California
Conditions
Multiple Myeloma
Interventions
JCARH125, JCARH125 + anakinra
Biological
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
20
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 16 more
Conditions
Metastatic Clear Cell Renal Cell Carcinoma
Interventions
IL-2, Stereotactic Ablative Body Radiation Therapy
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Lymphoma, Non-Hodgkin
Interventions
SB-485232, Rituximab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Chicago, Illinois • Indianapolis, Indiana
Conditions
Bacteremia
Interventions
Daptomycin, Vancomycin, Ceftaroline
Drug
Lead sponsor
Sharp HealthCare
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
La Mesa, California • San Diego, California
Conditions
Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum
Interventions
Aldesleukin, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Nivolumab, Oxaliplatin, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Asthma
Interventions
MCT, Clazakizumab, Broncho-Vaxom, Imatinib Mesylate, Cavosonstat, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years and older
Enrollment
950 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
29
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 17 more
Conditions
AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia
Interventions
Rabbit Anti thymocyte globulin, Busulfan, Fludarabine, Thiotepa, Melphalan, TCR alpha beta / CD19+ depleted haploidentical hematopoietic progenitor cell graft, memory-like natural killer cells, IL-2, Plerixafor, Granulocyte Colony-Stimulating Factor, CliniMACS
Drug · Biological · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Brain and Central Nervous System Tumors
Interventions
aldesleukin, muromonab-CD3, therapeutic tumor infiltrating lymphocytes, conventional surgery
Biological · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
3
States / cities
Denver, Colorado
Conditions
Large B-cell Lymphoma
Interventions
NT-I7, CAR T-cell therapy
Drug · Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
IO Resistant Squamous and Nonsquamous NSCLC
Interventions
TAK-928, Control Arm
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Jonesboro, Arkansas • Fair Oaks, California • Fountain Valley, California + 9 more
Conditions
Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Interventions
124I AT-01
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
Interventions
Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
Biological
Lead sponsor
Gregory Daniels
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
La Jolla, California
Conditions
Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
FATE-NK100, Interleukin-2
Biological · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Graft Versus Host Disease
Interventions
Interleukin-2
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
HIV Infections
Interventions
Recombinant interleukin-2 (rIL-2)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
78
States / cities
Los Angeles, California • Mill Valley, California • Oakland, California + 33 more
Conditions
Renal Cell Carcinoma
Interventions
EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC), Interleukin-2, Interferon-alpha
Biological · Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Omaha, Nebraska • Hackensack, New Jersey • Houston, Texas
Conditions
Mycobacterium Infections, Nontuberculous
Interventions
Recombinant human interleukin-7
Drug
Lead sponsor
Revimmune
Industry
Eligibility
18 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), Aldesleukin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 18 more
Completed No phase listed Observational Accepts healthy volunteers

Inflammatory Cytokines Associated With Perinatal Brain Injury

NCT01035697
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Cerebral Palsy
Interventions
Not listed
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 72 Hours
Enrollment
1,067 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
18
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 14 more
Conditions
Chronic Graft-versus-host-disease
Interventions
Extracorporeal Photopheresis (ECP), Interleukin-2
Procedure · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Conditions
Systemic Lupus Erythematosus
Interventions
LY3471851, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
23
States / cities
La Jolla, California • Palm Desert, California • Stanford, California + 18 more